跳至主要内容
临床试验/NL-OMON46337
NL-OMON46337尚未招募2 期

The physiology of glucagon-like peptide-l receptor expression in patients with endogenous hyperinsulinism: correlation with histopathology - Exendin-CHI

ucleaire geneeskunde en radiologie0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • - Biochemically and clinically proven endogenous congenital hyperinsulinism:
  • - Unresponsive to medical treatment (diazoxide)
  • - Indication for 18F-DOPA PET/CT based on mutation analysis
  • - Standard imaging (18F-DOPA PETICT) not older than 8 weeks
  • - <16 years old;- informed consent signed by parents or legal guardians of the patient.

排除标准

  • - Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous ABCCS/KCNJ11 mutation)
  • - Calculated creatinine clearance below 40 ml/min
  • - Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions based on CT)
  • - Age >16 years
  • - No signed informed consent

研究者

发起方
ucleaire geneeskunde en radiologie

相似试验